Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
REGULATORY
Japan Cabinet OKs Bill to Create Pandemic Response Agency
The Japanese Cabinet on February 7 approved a bill to create an infectious disease crisis management agency, which will serve as the command tower for pandemic responses. The bill will now be sent to the Diet for deliberations in the…
To read the full story
Related Article
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
- Deliberations Underway for Transfer of Some MHLW Functions to Boost Pandemic Responses: Vice Health Minister
August 10, 2022
- Govt Officially OKs Launch of Pandemic Response Agency, Japan CDC
June 20, 2022
- Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
- Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
REGULATORY
- Pariet’s Nonprescription Versions Approved 6 Years after Discussions Start
March 25, 2025
- AMED President Mishima Hints at Resignation
March 25, 2025
- FPMAJ Prods Drastic Review of Fiscal Framework before Honebuto 2025
March 25, 2025
- Difficult to “Visualize” Distribution, Production Costs in NHI Prices: Minister
March 25, 2025
- MHLW Panel Discusses Ways to Promote Clinical Trials
March 24, 2025
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…